National estimates on drug-related visits to hospital emergency departments (ED) are obtained from the Drug Abuse Warning Network (DAWN),1,2 a public health surveillance system managed by the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS). DAWN data* are based on a national sample of general, non-Federal hospitals operating 24-hour Emergency Departments (EDs).
In the first long-term follow-up of patients treated with buprenorphine/naloxone for addiction to opioid pain relievers, half reported that they were abstinent from the drugs 18 months after starting the therapy.
Advancement in the biomedical field, especially in medications development, comes in small increments. The many minor discoveries on the path to a new drug may not be individually newsworthy, but when those years of hard work culminate in a new treatment that changes how we practice medicine or improves public health, it is important to celebrate our success.